Thanks to Ora Moose for this story.

Jonathan Saltzman
June 06, 2018

"If, God forbid, there’s ever a nuclear war, a Lexington biotechnology startup will be able to sell a drug that’s been proven effective against radiation sickness.
It’s definitely a “good news/bad news” situation, but it’s better than nothing.
The Food and Drug Administration has lifted the final regulatory hurdle for Partner Therapeutics Inc., or PTx, to market Leukine as a treatment for radiation poisoning in adults and children, the company said on Wednesday."

Read more: